急性心肌梗死合并血小板增多症诊疗进展  

Progress in Practical Considerations for Diagnosis and Treatment of Acute Myocardial Infarction Combined with Thrombocytosis

作　　者：王咏[1] 郭蔚 周华[1] WANG Yong;GUO Wei;ZHOU Hua(Department of Cardiology,Shuguang Hospital,Shanghai University of Traditonal Chinese Medicine,Shanghai 201203,China;Department of Cardiology,Shanghai East Hospital Affiliated to Tongji University,Shanghai 200120,China)

机构地区：[1]上海中医药大学附属曙光医院心内科,上海201203 [2]上海同济大学附属东方医院心内科,上海200120

出　　处：《心血管病学进展》2018年第3期416-420,共5页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金面上项目(81373625);国家自然科学基金青年科学基金资助项目(81403363)

摘　　要：急性心肌梗死合并血小板增多症病理机制存在其特殊性,危害较大,多见于合并心血管病危险因素或既往有血栓病史的血小板增多症患者,再次发生血栓及出血风险较高,值得深入研究。本病多于急性心肌梗死发作时,查外周血血小板数目增高偶然发现,其冠状动脉可见大量血小板性血栓,可无明显斑块狭窄,治疗存在其特殊性,注重抗血小板聚集药物及骨髓抑制药物的使用。目前临床上对于本病多为经验性诊断和治疗,仍需要大规模临床研究以制定规范化的诊疗措施。Acute myocardial irfarcdon （AMI） combined with thrombocytosis occurs predominantly in thrombocytosis patients with cardiovascular risk factors or thrombosis history. Further discussion of the diagnosis and treatment of this disease is deserved as it has specific characteristics in pathomechanism and high recurrence risk of blood clots or hemorrhage. Thrombocytosis mostly happens by chance for AMI patients who have a large number of platelet tlirombus and no obviously stenosis by atlieromatous plaque in the coronary artery, More attention should be paid to the application of anti-platelet aggregation medicine and anti-myelopoie sis medicine. The current diagnosis and tratment for this disease is experiential and large-scale clinical research is needed to develop standard diagnosis and treatment measures.

关 键 词：急性心肌梗死 原发性血小板增多症 继发性血小板增多症 

分 类 号：R542.22[医药卫生—心血管疾病]